The Pharma-Grade Cellulose Powder Market Is Seeing Strong Growth, From $1.19 Billion In 2024 To $1.62 Billion In 2029

June 19, 2025 10:11 AM BST | By EIN Presswire
 The Pharma-Grade Cellulose Powder Market Is Seeing Strong Growth, From $1.19 Billion In 2024 To $1.62 Billion In 2029
Image source: EIN Presswire

LONDON, GREATER LONDON, UNITED KINGDOM, June 19, 2025 /EINPresswire.com/ -- The pharma-grade cellulose powder market has experienced remarkable growth in recent years, with market size expanding from $1.19 billion in 2024 to an estimated $1.27 billion in 2025. This represents a compound annual growth rate CAGR of 6.5%. Factors such as increased demand for tablet binders, rising production of generic drugs, advancements in pharmaceutical research, development and regulatory approvals for cellulose-based excipients, combined with expanded manufacturing capacity, have largely contributed to this progress in the historic period.

What Is The Projected Future Growth Of The Pharma-Grade Cellulose Powder Market Size?
In an exciting forecast, the pharma-grade cellulose powder market size is expected to see substantial growth in the forthcoming years, rising to $1.62 billion by 2029, at a CAGR of 6.2%. This future growth can largely be attributed to a surge in personalized medicine, adoption of sustainable excipients, expansion in biologics and biosimilars, and escalated focus on oral drug delivery innovations. Additionally, growing investments in pharmaceutical infrastructure in emerging markets as well as increasing demand for excipient-grade materials in drug formulation are also anticipated to play a key role.

Get Your Free Sample Market Report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=24373&type=smp

What Are The Key Drivers Propelling The Growth Of The Pharma-Grade Cellulose Powder Market?
Undeniably, the escalating demand in the pharmaceutical production industry will catalyse the growth of the pharma-grade cellulose powder market moving forward. As the pharmaceutical production involves meticulous formulation, synthesis, and quality control of active ingredients and excipients to ensure safety, efficacy, and regulatory compliance, pharma-grade cellulose powder lends significant support as a reliable binder, filler, and stabilizer. To illustrate this, data from the European Federation of Pharmaceutical Industries and Associations EFPIA reveals a yearly increase in total pharmaceutical production in Europe from $393,857 million in 2022 to $422,803 million in 2023.

What Key Player Strategies Are Driving The Pharma-Grade Cellulose Powder Market?
The key industry players operating in the pharma-grade cellulose powder market include Roquette Frères, Ashland Global, JRS Pharma, Ankit Pulps & Boards Pvt. Ltd., DFE Pharma, Sigachi Industries Ltd., Accent Microcell Ltd., Maple Biotech Pvt. Ltd., Mingtai Chemical Co. Ltd., Patel Chem Specialties Limited, CelluTech, RanQ, and Aromatic Cellulose Pvt. Ltd. among others. These major companies are focusing on the development of new, microcrystalline cellulose facilities to expand their production capacity and strengthen their supply chain capabilities for pharmaceutical excipients. One notable development includes the inauguration of India’s largest microcrystalline cellulose MCC manufacturing plant at Nagpur by Nitika Pharmaceuticals Specialties in September 2023.

Order Your Report Now For A Swift Delivery:
https://www.thebusinessresearchcompany.com/report/pharma-grade-cellulose-powder-global-market-report

How Is The Pharma-Grade Cellulose Powder Market Segmented?
The report provides comprehensive segmentation details of the pharma-grade cellulose powder market:

1 By Product Type: Microcrystalline Cellulose MCC, Carboxymethyl Cellulose CMC, Hydroxypropyl Methylcellulose HPMC, Hydroxypropyl Cellulose HPC
2 By Functionality: Binding Agent, Thickening Agent, Stabilizer, Disintegrant, Coating Agent
3 By Application: Pharmaceuticals, Nutraceuticals, Cosmetics, Other Applications
4 By End-User: Contract Research Organizations CROs, Pharmaceutical and Biotechnology Companies, Academic And Research Institutions, Manufacturers Of Dietary Supplements, Food And Beverage Industries

What Are The Regional Insights In The Pharma-Grade Cellulose Powder Market?
On the regional front, North America prevailed as the largest region in the pharma-grade cellulose powder market in 2024, with other significant regions of the market spanning across Asia-Pacific, Western Europe, Eastern Europe, and South America, as well as the Middle East and Africa.

Browse Through More Similar Reports By The Business Research Company:
Pharma ADMET Testing Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/pharma-admet-testing-global-market-report

Automation In Biopharma Industry Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/automation-in-biopharma-industry-global-market-report

Cellulose Acetate Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/cellulose-acetate-global-market-report

About The Business Research Company
Learn More About The Business Research Company. With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Contact us at:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 3156230293
Asia +44 2071930708
Europe +44 2071930708
Email us at [email protected]

Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Oliver Guirdham
The Business Research Company
+44 20 7193 0708
[email protected]
Visit us on social media:
LinkedIn
Facebook
X

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.


Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Limited, Company No. 12643132 (“Kalkine Media, we or us”) and is available for personal and non-commercial use only. Kalkine Media is an appointed representative of Kalkine Limited, who is authorized and regulated by the FCA (FRN: 579414). The non-personalized advice given by Kalkine Media through its Content does not in any way endorse or recommend individuals, investment products or services suitable for your personal financial situation. You should discuss your portfolios and the risk tolerance level appropriate for your personal financial situation, with a qualified financial planner and/or adviser. No liability is accepted by Kalkine Media or Kalkine Limited and/or any of its employees/officers, for any investment loss, or any other loss or detriment experienced by you for any investment decision, whether consequent to, or in any way related to this Content, the provision of which is a regulated activity. Kalkine Media does not intend to exclude any liability which is not permitted to be excluded under applicable law or regulation. Some of the Content on this website may be sponsored/non-sponsored, as applicable. However, on the date of publication of any such Content, none of the employees and/or associates of Kalkine Media hold positions in any of the stocks covered by Kalkine Media through its Content. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media.
The content published on Kalkine Media also includes feeds sourced from third-party providers. Kalkine does not assert any ownership rights over the content provided by these third-party sources. The inclusion of such feeds on the Website is for informational purposes only. Kalkine does not guarantee the accuracy, completeness, or reliability of the content obtained from third-party feeds. Furthermore, Kalkine Media shall not be held liable for any errors, omissions, or inaccuracies in the content obtained from third-party feeds, nor for any damages or losses arising from the use of such content. Some of the images/music/video that may be used in the Content are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music or video used in the Content unless stated otherwise. The images/music/video that may be used in the Content are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.
This disclaimer is subject to change without notice. Users are advised to review this disclaimer periodically for any updates or modifications.


Sponsored Articles


Investing Ideas

Previous Next